StockData

KALA BIO, Inc. (KALA) stock

KALANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 19, 2026Score 5/30
$3.26−0.17 (-4.96%)

Close on Nov 18, 2026Market cap $63.05MP/E –Yield –

Kala Bio revenue

Revenue is the money a company takes in from selling its products and services, before any costs are deducted.

Kala Bio's revenue for the twelve months ending Dec 31, 2022 was $3.89M, down 65.4% year over year. For fiscal 2025 it was $0. The highest annual figure on record is $11.24M in fiscal 2021.

Annual revenue

PeriodPeriod endValueChange
FY2025Dec 31, 2025$0–
FY2024Dec 31, 2024$0–
FY2023Dec 31, 2023$0-100.0%
FY2022Dec 31, 2022$3.89M-65.4%
FY2021Dec 31, 2021$11.24M+76.7%
FY2020Dec 31, 2020$6.36M+4.7%
FY2019Dec 31, 2019$6.07M–
FY2017Dec 31, 2017$0–
FY2016Dec 31, 2016$0-100.0%
FY2015Dec 31, 2015$45.00K–

Quarterly revenue

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2022Dec 31, 2022$0-100.0%
Q3 FY2022Sep 30, 2022$420.00K-86.3%
Q2 FY2022Jun 30, 2022$2.10M-31.2%
Q1 FY2022Mar 31, 2022$1.37M-58.0%
Q4 FY2021Dec 31, 2021$1.86M-17.1%
Q3 FY2021Sep 30, 2021$3.07M+38.2%
Q2 FY2021Jun 30, 2021$3.05M+266.3%
Q1 FY2021Mar 31, 2021$3.27M+204.9%
Q4 FY2020Dec 31, 2020$2.24M+89.7%
Q3 FY2020Sep 30, 2020$2.22M+53.0%
Q2 FY2020Jun 30, 2020$833.00K-59.5%
Q1 FY2020Mar 31, 2020$1.07M-22.7%
Q4 FY2019Dec 31, 2019$1.18M–
Q3 FY2019Sep 30, 2019$1.45M–
Q2 FY2019Jun 30, 2019$2.06M–
Q1 FY2019Mar 31, 2019$1.39M–

More Kala Bio figures

See a number that looks wrong?